Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Evolent Health, Inc. (EVH)

Evolent Health Q2 revenue rises to $652.5 million; raises 2026 revenue guidance

Mixed Impact 4 of 5 earnings Written later

Evolent Health reported second-quarter 2026 revenue of $652.5 million, up from $444.3 million a year earlier, and its net loss narrowed to $28.4 million from $51.1 million. Adjusted EBITDA fell to $28.1 million from $37.5 million, and the company raised its 2026 revenue guidance while tightening its Adjusted EBITDA range.

Key points

  • Q2 2026 revenue was $652.5 million versus $444.3 million in Q2 2025; net loss attributable to common shareholders was $28.4 million, or $0.25 per share, versus $51.1 million, or $0.44 per share.
  • Adjusted EBITDA was $28.1 million, with a 4.3% margin, compared with $37.5 million and an 8.5% margin a year earlier.
  • 2026 revenue guidance was raised to $2.6 billion to $2.7 billion; Adjusted EBITDA guidance was tightened to $120 million to $135 million.
  • The company expects 2027 revenue growth of over 25% compared with 2026, and a 2027 Adjusted EBITDA midpoint at or above $150 million.

The filing

CompanyEvolent Health, Inc. (EVH)
Form8-K, current report
Filed with the SECAug 6, 2026, 7:03 AM ET
Accession number0001628908-26-000084

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.